Home>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Sodium Channel>>Eslicarbazepine acetate

Eslicarbazepine acetate (Synonyms: BIA 2-093)

Catalog No.GC13809

antiepileptic drug

Products are for research use only. Not for human use. We do not sell to patients.

Eslicarbazepine acetate Chemical Structure

Cas No.: 236395-14-5

Size Price Stock Qty
10mM (in 1mL DMSO)
$38.00
In stock
100mg
$172.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Eslicarbazepine acetate, an antiepileptic drug, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel.

Eslicarbazepine acetate is an antiepileptic drug. It is a prodrug which is activated to eslicarbazepine (S-licarbazepine), an active metabolite of oxcarbazepine. Eslicarbazepine acetate is a prodrug for (S)-(+)-licarbazepine, the major active metabolite of oxcarbazepine. Its mechanism of action is therefore identical to that of oxcarbazepine. Eslicarbazepine acetate may not produce as high peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine which could theoretically improve tolerability[1].

References:
[1]. Sibhghatulla Shaikh, et al. Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study. CNS & Neurological Disorders Drug Targets Volume 13 , Issue 7 , 2014.

Reviews

Review for Eslicarbazepine acetate

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Eslicarbazepine acetate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.